Navigation Links
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
Date:5/1/2008

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

"Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments," said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. "We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options."

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:

May 7, 2008; 12:00 p.m. ET

Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD:

Parental Impressions and Experiences

APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD

APA Oral Presentation Session # 28

Methylphenidate Transdermal System:

May 7, 2008; 12:00 p.m. ET

Long-Term Treatment Effects of the Methylphenidate Transdermal System in

Boys and Girls with ADHD

APA Poster Presentation # NR6-018

Guanfacine Extended Release:

May 7, 2008; 12:00 p.m. ET

Guanfacine Extended Release:
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
2. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
5. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
6. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
7. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The Fastest Fat Loss Week Ever, released by ... the Xtreme Fat Loss Diet, has been causing a lot ... that claims to help one lose belly fat in only ... prompting an investigative review. , "Our Fastest Fat Loss ... researching and experimenting with these methods on their clients with ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had the ... contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, sponsored ... of which Wickstrom is the founder. Making appearances at ... EcoLuxe Lounge is a gathering of some of the ... and services. Among the many roles that she has ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog post has ... qualify for auto insurance as a single parent. ... online, without having to follow a special process. The ... reduce their auto insurance expenses. The tips are presented ... , Clients can now visit an insurance brokerage website ...
(Date:4/24/2015)... Olive Fertility Centre is proud to announce that ... been honoured for his pioneering work in the field ... , “We are very pleased to have this ... at the forefront of fertility research and treatment for ... of Fertile Futures--a Canadian non-profit organization that provides fertility ...
Breaking Medicine News(10 mins):Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2
... - Fat substitutes used in popular snack foods to help ... Purdue University research. "These substitutes are meant to mimic ... in fat while providing a lower number of calories, but ... Swithers, professor of psychological sciences. "We didn,t study this in ...
... , WEDNESDAY, June 22 (HealthDay News) -- Researchers searching ... a promising possibility: an impairment in the ability of ... each other. In the study, researchers did brain ... 30 typically developing kids and 13 children with significant ...
... bypass surgery is considered the gold standard for most patients ... serious types of heart disease and one that affects thousands. ... favorable long-term outcomes for lower-risk patients with this condition who ... A more minimally invasive procedure than surgery, angioplasty ...
... Children born to mothers who smoked during pregnancy have lower ... of heart attack and stroke later in life, a new ... children and found that those whose mothers smoked during pregnancy ... compared to a normal level of 1.5 mmol/L in children ...
... The University of New Hampshire has launched a ... Sciences (CAAS) to promote international research in agricultural development ... College of Life Sciences and Agriculture (COLSA) at UNH ... of the CAAS Institute for Agricultural Resources and Regional ...
... UNC Lineberger Comprehensive Cancer Center, offers hope for people with ... disease characterized by excessive production of red blood cells. ... of stroke, and in some cases the disease is a ... cases are associated with a mutation in the JAK2 gene, ...
Cached Medicine News:Health News:Study: Trying to lose weight? Lose the fat substitutes 2Health News:Poor Brain 'Sync' a Possible Sign of Autism 2Health News:Poor Brain 'Sync' a Possible Sign of Autism 3Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 2Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 3Health News:UNH launches joint Sustainable Agro-Ecosystems Lab with Chinese Academy 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
... differential detection of circulating ... an antigen that is common ... malaria:plasmodium falciparum (P.f), plasmodium vivax ... Plasmodium malariae (P.m) in whole ...
Medicine Products: